Genmab — Maj 2017
-
Tak for link. En hurtigere behandling af ansøgninger må vel anses som positivt for Genmab i de kommende år.
-
Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody
Antibody, in Participants With Relapsed or Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03145181?term=JNJ-64007957&rank=1 T
his seems new? -
Så falder der vel en milepæl til Genmab når den første patienter behandles...
-
De plejer at være på 2-3 mio. USD
-
meanwhile Tecentriq phase III in advanced bladder cancer failed on overall survival.
http://www.roche.com/investors/updates/inv-update-2017-05-10.htm -
-
-
Bliver spændende hvad de guider ud for resten af 2017, når regnskabet lander. Mon ikke os Jan har en kommentar omkring pipeline, som kan være interessant.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
Very happy for that